Ірина Давиденко

2.6k citations

33 papers · 1.6k · 1 hit paper · h-index 16

Impact in

Otorhinolaryngology top 2%
- Head and Neck Cancer Studies
Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology

Papers in

Pulmonary and Respiratory Medicine 18
- Lung Cancer Treatments and Mutations 9
- Gastric Cancer Management and Outcomes 6
Oncology 18
- Colorectal Cancer Treatments and Studies 11
- Pancreatic and Hepatic Oncology Research 7
- Cancer Treatment and Pharmacology 4

Co-authors: Kelly S. Oliner (9 shared papers)Philip J. Johnson (2 shared papers)Leonard B. Saltz (2 shared papers)Jennifer J. Knox (2 shared papers)J. Lacava (2 shared papers)Marinela Capanu (2 shared papers)Ghassan K. Abou‐Alfa (2 shared papers)Thomas W. T. Leung (2 shared papers)
Journals: Journal of Clinical Oncology (11 papers)Annals of Oncology (8 papers)European Journal of Cancer (4 papers)Clinical Cancer Research (2 papers)The Lancet Oncology (2 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Ірина Давиденко

29 papers receiving 1.6k citations

Ірина Давиденко's Hit Papers

align trajectories log scale

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial 2013 · 314 citations

Peers

Countries citing papers authored by Ірина Давиденко

Since Specialization

Citations

This map shows the geographic impact of Ірина Давиденко's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ірина Давиденко with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ірина Давиденко more than expected).

Fields of papers citing papers by Ірина Давиденко

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ірина Давиденко. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ірина Давиденко. The network helps show where Ірина Давиденко may publish in the future.

Co-authors

The 25 scholars most cited alongside Ірина Давиденко, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ірина Давиденко Line = papers co-authored together Ірина Давиденко links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma JAMA ·Ghassan K. Abou‐Alfa, Philip J. Johnson, Jennifer J. Knox, Marinela Capanu, Ірина Давиденко, J. Lacava, Thomas W. T. Leung, Bolorsukh Gansukh, Leonard B. Saltz	2010	343
2	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial The Lancet Oncology ·Jan B. Vermorken, Jan Stöhlmacher-Williams, Ірина Давиденко, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Składowski, Makoto Tahara, Vasant R. Pai, Sandrine Faivre, C. Blajman, Arlene A. Forastiere, B. Stein, Kelly S. Oliner, Zhiying Pan, Bruce Allen Bach Hit paper breakdown →	2013	314
3	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study The Lancet Oncology ·Timothy Iveson, Ross C. Donehower, Ірина Давиденко, S. Tjulandin, Andrzej Deptała, Mark Harrison, S S Nirni, K C Lakshmaiah, Anne Thomas, Yizhou Jiang, Min Zhu, Rui Tang, Abraham Anderson, Sarita Dubey, Kelly S. Oliner, Elwyn Loh	2014	216
4	Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. Journal of Clinical Oncology ·David Cunningham, Niall C. Tebbutt, Ірина Давиденко, André M. Murad, Salah‐Eddin Al‐Batran, David H. Ilson, Sergei Tjulandin, Evgeny Gotovkin, Bogusława Karaszewska, Igor Bondarenko, Mohamedtaki Abdulaziz Tejani, Anghel Adrian Udrea, Mustapha Tehfé, Nigel Baker, Kelly S. Oliner, Yilong Zhang, Tien Hoang, Roger Sidhu, Daniel Virgil Thomas Catenacci	2015	120
5	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer Clinical Cancer Research ·Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Élena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero	2014	92
6	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer Gynecologic Oncology ·Rebecca Kristeleit, Ірина Давиденко, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko, Michael J. Goodheart, В. А. Горбунова, C A Penning, Jack Shi, Xiangdong Liu, Robert Newton, Yufan Zhao, Janet Maleski, Lance Leopold, Russell J. Schilder	2017	78
7	Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial Clinical Cancer Research ·Josep Tabernero, Rocio García‐Carbonero, James T. Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Ірина Давиденко, Ramón Salazar, Л. Ю. Владимирова, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O’Dwyer	2013	69
8	Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy Annals of Oncology ·Kimberly Blackwell, Vladimir Semiglazov, Dmitriy Krasnozhon, Ірина Давиденко, L. Nelyubina, Roumen Nakov, G. Stiegler, Pritibha Singh, Arnd Schwebig, Simon Krämer, Nadia Harbeck	2015	65
9	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study International Journal of Gynecological Cancer ·Amit M. Oza, Frédèric Selle, Ірина Давиденко, Jacob Korach, César Mendiola, Patricia Pautier, Ewa Chmielowska, Aristotelis Bamias, Andrea DeCensi, Zanete Zvirbule, Antonio González-Martı́n, Roberto Hegg, Florence Joly, Claudio Zamagni, Angiolo Gadducci, Nicolas Martin, Stephen Robb, Nicoletta Colombo	2016	55
10	Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal Cancer Who Are Receiving Fluorouracil-Based Chemotherapy Journal of Clinical Oncology ·Douglas E. Peterson, Nicholas P. Barker, L. I. Akhmadullina, Irina Rodionova, Н. З. Шерман, Ірина Давиденко, Galina N. Rakovskaya, E. Gotovkin, С. А. Шинкарев, М. В. Копп, Eugeny P. Kulikov, Vladimir Moiseyenko, Joseph M. Gertner, Igor Firsov, Tamara Tuleneva, A. O. Yarosh, Chee-Wai Woon	2009	51
11	A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. Journal of Clinical Oncology ·Cathy Eng, Eric Van Cutsem, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Kelly S. Oliner, L. Chen, Jing Huang, Ian McCaffery, Elwyn Loh, Dominic Smethurst, Josep Tabernero	2011	31
12	Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma Annals of Oncology ·David Propper, Ірина Давиденко, John Bridgewater, Limas Kupčinskas, A. Fittipaldo, Carina Hillenbach, Barbara Klughammer, Michel Ducreux	2014	25
13	6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma European Journal of Cancer ·Timothy Iveson, Ross C. Donehower, Ірина Давиденко, S. Tjulandin, Andrzej Deptała, M. Harrison, Elwyn Loh, Ya Jiang, Kelly S. Oliner, S. Dubey	2011	23
14	An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM) Journal of Clinical Oncology ·J. B. Vermorken, J. Stöhlmacher, Ірина Давиденко, Eric Winquist, Lisa Licitra, V. R. Pai, Krzysztof Składowski, C. Blajman, Sandrine Faivre, Jennifer Gansert	2009	19
15	RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Journal of Clinical Oncology ·David Cunningham, Salah‐Eddin Al‐Batran, Ірина Давиденко, David H. Ilson, André M. Murad, Niall C. Tebbutt, Yizhou Jiang, Elwyn Loh, Sarita Dubey, (unknown)	2013	17
16	Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial. Journal of Clinical Oncology ·Jan Stoehlmacher-Williams, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Eric Winquist, Lisa Licitra, Ірина Давиденко, Krzysztof Składowski, Makoto Tahara, Sandrine Faivre, Kelly S. Oliner, Zhiying Pan, Bruce Allen Bach, Jan B. Vermorken	2012	16
17	Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma Ghassan K. Abou‐Alfa, Philip J. Johnson, Jennifer J. Knox, Marinela Capanu, Ірина Давиденко, J. Lacava, Thomas W. T. Leung, Leonard B. Saltz	2013	12
18	Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment. Journal of Clinical Oncology ·Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, Mitch Raponi, Tone Ikdahl, Igor Bondarenko, Ірина Давиденко, В. Ю. Бондарь, August Garin, Stefan Boeck, Volker Heinemann, Claudio Bassi, T.R. Jeffry Evans, Cynthia Voong, Paramjit Kaur, Jeffrey D. Isaacson, Andrew R. Allen	2013	10
19	Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma Annals of Oncology ·David Cunningham, S-E. Al-Batran, Ірина Давиденко, David H. Ilson, A.M. Murad, Niall C. Tebbutt, Nigel Baker, Rajul K. Jain, Tien Hoang	2014	8
20	A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial European Journal of Cancer ·Josep Tabernero, Rocio García‐Carbonero, C.H. Könne, P J O'Dwyer, Alberto Sobrero, E. Van Cutsem, Oleg Gladkov, Ірина Давиденко, Ramón Salazar, J Cassidy	2011	7

About Ірина Давиденко

Ірина Давиденко is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hepatology, Cancer Research and Otorhinolaryngology, having authored 33 papers that have together received 1.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (9 papers), Pancreatic and Hepatic Oncology Research (7 papers), Gastric Cancer Management and Outcomes (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Cancer Treatment and Pharmacology (4 papers), Cancer Research and Treatments (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). The work is most often cited by research in Otorhinolaryngology (242 citations), Hepatology (432 citations), Oncology (807 citations), Pulmonary and Respiratory Medicine (583 citations) and Biological Psychiatry (40 citations). Ірина Давиденко has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Kelly S. Oliner, Philip J. Johnson, Leonard B. Saltz, Jennifer J. Knox, J. Lacava, Marinela Capanu, Ghassan K. Abou‐Alfa, Thomas W. T. Leung, Bolorsukh Gansukh and Elwyn Loh. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Clinical Cancer Research and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Ірина Давиденко

Impact in

Papers in i

In The Last Decade

Ірина Давиденко

Ірина Давиденко's Hit Papers

Peers

Countries citing papers authored by Ірина Давиденко

Fields of papers citing papers by Ірина Давиденко

All Works

About Ірина Давиденко

Explore authors with similar magnitude of impact

Papers in